Financial Advocates Investment Management Regeneron Pharmaceuticals, Inc. Transaction History

Financial Advocates Investment Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$902.69 - $993.35 $902 - $993	-1 Reduced 0.25%	392 $377,000
Q4 2023 Feb 08, 2024	BUY	$775.18 - $881.7 $62,014 - $70,536	80 Added 25.56%	393 $345,000
Q3 2023 Oct 27, 2023	BUY	$692.45 - $844.37 $2,769 - $3,377	4 Added 1.29%	313 $257,000
Q2 2023 Aug 07, 2023	SELL	$700.03 - $830.35 $63,002 - $74,731	-90 Reduced 22.56%	309 $222,000
Q1 2023 May 11, 2023	BUY	$680.49 - $826.97 $271,515 - $329,961	399 New	399 $327,000
Q2 2022 Aug 12, 2022	SELL	$548.35 - $738.84 $157,376 - $212,047	-287 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$595.12 - $698.43 $170,799 - $200,449	287 New	287 $200,000
Q4 2021 Feb 14, 2022	SELL	$543.48 - $670.97 $267,392 - $330,117	-492 Closed	0 $0
Q3 2021 Nov 04, 2021	BUY	$574.03 - $680.96 $26,979 - $32,005	47 Added 10.56%	492 $298,000
Q2 2021 Aug 03, 2021	BUY	$472.8 - $558.54 $210,396 - $248,550	445 New	445 $248,000

1,534

83.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.3B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Financial Advocates Investment Management, based on Form 13F filings with the SEC.

Stay updated on Financial Advocates Investment Management with notifications on news.